Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A

As of June 30, 2026, Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class H carries a market capitalization of 8.81B, placing it among publicly traded companies globally. Its enterprise value stands at 7.41B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class H has 3.72B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class H maintains a current ratio of 6.53, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class H's stock has declined approximately 28.57% over the past 52 weeks. The 50-day moving average sits at 2.54, while the 200-day moving average is 2.71.

As of June 30, 2026, Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class H holds 1.41B in cash and equivalents against 13.85M in total debt, resulting in a net debt position of -1.41B. Total book value stands at 2.49B, with working capital of 1.51B providing operational flexibility.